Literature DB >> 28260205

Cabergoline for hyperprolactinemia: getting to the heart of it.

Lisa B Nachtigall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28260205     DOI： 10.1007/s12020-017-1271-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  19 in total

Review 1.  Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.

Authors:  Vincent Setola; Bryan L Roth
Journal:  Expert Opin Drug Metab Toxicol       Date:  2005-10       Impact factor: 4.481

2.  Dopamine agonists and the risk of cardiac-valve regurgitation.

Authors:  René Schade; Frank Andersohn; Samy Suissa; Wilhelm Haverkamp; Edeltraut Garbe
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

3.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Authors:  Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

4.  Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.

Authors:  Laurent Vroonen; Patrizio Lancellotti; Monica Tomé Garcia; Raluca Dulgheru; Matilde Rubio-Almanza; Ibrahima Maiga; Julien Magne; Patrick Petrossians; Renata Auriemma; Adrian F Daly; Albert Beckers
Journal:  Endocrine       Date:  2016-10-05       Impact factor: 3.633

5.  Carcinoid valve disease.

Authors:  J Wells Askew; Heidi M Connolly
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

6.  Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.

Authors:  Renata S Auriemma; Rosario Pivonello; Ylenia Perone; Ludovica F S Grasso; Lucia Ferreri; Chiara Simeoli; Davide Iacuaniello; Maurizio Gasperi; Annamaria Colao
Journal:  Eur J Endocrinol       Date:  2013-08-28       Impact factor: 6.664

7.  A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.

Authors:  William M Drake; Craig E Stiles; John S Bevan; Niki Karavitaki; Peter J Trainer; D Aled Rees; Tristan I Richardson; Stephanie E Baldeweg; Nemanja Stojanovic; Robert D Murray; Andrew A Toogood; Niamh M Martin; Bijay Vaidya; Than S Han; Rick P Steeds; F C Baldeweg; U E Sheikh; N Kyriakakis; S K Parasuraman; L Taylor; N Butt; S Anyiam
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

8.  Cabergoline and the risk of valvular lesions in endocrine disease.

Authors:  Patrizio Lancellotti; Elena Livadariu; Muriel Markov; Adrian F Daly; Maria-Cristina Burlacu; Daniela Betea; Luc Pierard; Albert Beckers
Journal:  Eur J Endocrinol       Date:  2008-05-02       Impact factor: 6.664

9.  Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.

Authors:  Lisa B Nachtigall; Elena Valassi; Janet Lo; David McCarty; Jonathan Passeri; Beverly M K Biller; Karen K Miller; Andrea Utz; Steven Grinspoon; Elizabeth A Lawson; Anne Klibanski
Journal:  Clin Endocrinol (Oxf)       Date:  2009-04-17       Impact factor: 3.478

10.  Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.

Authors:  F Bogazzi; S Buralli; L Manetti; V Raffaelli; T Cigni; M Lombardi; F Boresi; S Taddei; A Salvetti; E Martino
Journal:  Int J Clin Pract       Date:  2008-05-06       Impact factor: 2.503
View more
  1 in total

1.  Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial.

Authors:  Mervat Ali Mohamed Elsersy
Journal:  J Obstet Gynaecol India       Date:  2017-06-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.